HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on aTyr Pharma (NASDAQ:LIFE) and maintained a $35 price target.
September 14, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
aTyr Pharma's stock rating has been reiterated as Buy by HC Wainwright & Co. with a maintained price target of $35.
The reiteration of a Buy rating and maintenance of a $35 price target by HC Wainwright & Co. indicates a positive outlook for aTyr Pharma. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100